title: Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
abstract: Transitional cell tumors of the ovary include benign, borderline (atypically proliferating), and malignant Brenner tumors (BT), as well as transitional cell carcinoma (TCC). Some TCCs could conceivably be examples of malignant BT where the benign component has been overgrown. Our objectives were: (A) compare the immunophenotypes of BT and TCC and (B) examine a large cohort of ovarian carcinomas for cases with the immunophenotype of BT and transitional features but lacking a benign BT component. Seven BTs (3 benign, 3 borderline/atypically proliferating, 1 malignant) and 7 TCCs were stained for WT1, ER, p53, and p16(INK4a). The BTs were negative for WT1, p53 overexpression, ER (except for weak positivity in 1), and negative or weakly positive for p16(INK4a). In contrast, the TCCs stained as follows: 4/6 positive for WT1, 5/7 positive for ER, 2/7 strongly positive for p16(INK4a), and 6/7 showed abnormal p53, an immunophenotype resembling that of high-grade serous carcinoma. A database of 500 cases of ovarian carcinoma was searched and 116 showed an immunoprofile characteristic of BT: WT1 negative, ER negative, p16(INK4a) or weak positive, p53 negative (77 clear cell carcinoma, 14 endometrioid carcinoma, 12 mucinous carcinoma, 8 high-grade serous carcinoma). None of these tumors showed transitional features on review, indicating that if examples of malignant BT where there has been overgrowth of benign BT components exist, they are rare. Our results suggest that BT and TCC are unrelated, and should not be combined for classification purposes.
authors.affiliation: Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver BC, Canada.
authors.forename: Rola H
authors.initials: RH
authors.lastname: Ali
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Seidman
authors.forename: Margaret
authors.initials: M
authors.lastname: Luk
authors.forename: Steve
authors.initials: S
authors.lastname: Kalloger
authors.forename: C Blake
authors.initials: CB
authors.lastname: Gilks
mesh_terms: D001948:Brenner Tumor / Q000737:chemistry / Q000473:pathology*; D002295:Carcinoma, Transitional Cell / Q000737:chemistry / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018284:Cystadenocarcinoma, Serous / Q000737:chemistry / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D053554:Keratin-20 / Q000032:analysis; D009363:Neoplasm Proteins / Q000032:analysis; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000473:pathology*; D011960:Receptors, Estrogen / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D053554:Keratin-20; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D016159:Tumor Suppressor Protein p53